[Clinical efficacy and safety of eculizumab in pediatric atypical hemolytic uremic syndrome].

PubMed 2026

View at publisher Summarise with VIRAT

Authors: J Chen, C Y Wang, J L Liu, X Y Fang, Yihui Zhai, Q F Miao, X S Tang, J L Liu, R F Dai, X L Han, Qian Shen, Hong Xu

DOI: 10.3760/cma.j.cn112140-20251016-00911

Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

ECZ demonstrates favorable efficacy and tolerability in pediatric aHUS. The application of ECZ may contribute to improve the prognosis of aHUS.

Fields of Study & Subjects

Complement system in diseases Renal Diseases and Glomerulopathies Coagulation Bradykinin Polyphosphates and Angioedema

Publication details

Journal / source: PubMed
Volume: 64
Issue: 4
Pages: 431–435
Publication date: 14 March 2026
Language: ZH